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Plants are natural reservoirs of a diversity of compounds, many of which have 
pharmacological/nutraceutical activities towards a variety of diseases. One important 
class of plant bioactive compounds is polyphenols. The term phenol is used to describe 
a structure with at least one aromatic ring containing one or more hydroxyl groups 
attached and the flavonoids, with several aromatic rings, represent a well-known 
subgroup of bioactive polyphenols. Other compounds, including hydroxycinnamates 
and phenolic acids, with only one phenolic ring are also referred to as polyphenols. 
These phytochemicals occur naturally in plants and epidemiological, pre-clinical and 
clinical studies have shown their importance for human health as they reduce the 
incidence and prevalence of cardiovascular diseases, cancer, diabetes, inflammation 
and age-related disorders. Modern pharmacopeia has received significant input from 
natural small molecules (such as polyphenols); however, the process of identifying 
novel bioactive compounds from biological sources has been a central challenge in the 
discovery of natural products. Moreover the exploitation of polyphenols as sources of 
molecules with pharmacological/nutraceutical interest depends on effective methods 
for compounds extraction to be further tested as regard their chemical and biological 
activities. Additionally, the use of fractionation procedures coordinated with 
bioactivity/antimicrobial screenings – bio-guided fractionation – is required for the 
identification of single compounds with therapeutic potential. Once identified, the 
pharmacokinetics and modus operandi of compounds need to be gathered to support 
the rational design and synthesis of medicinal chemistry derivatives. Alternatively, 
large-scale production of potential bioactive polyphenols can be achieved by means of 
synthetic biology. At last, technologies of controlled delivery must ensure that the 
compounds are carried to the site of action. The ultimate goal of this pipeline is to 
discover and make available to society therapeutic alternatives for chronic diseases 
including cancer, neurodegenerative, cardiovascular, and metabolic diseases. 
The thematic issue is a journey in the field of polyphenols as bioactive compounds for 
health, exploring the current strategies for identification, characterization, 
improvement and production of these protective molecules. 
Foito et al. described the state of art methodologies used for structural elucidation and 
annotation of novel bioactive compounds. An overview of the metabolomics toolbox 
available, from hyphenated mass spectrometry (MS) and nuclear magnetic resonance 
(NMR)-based analytical technologies, is described alongside with technical 
developments in instrumentation and data processing. In addition, the authors explore 
the importance of the integration of these tools in the bioprospection and drug 
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discovery workflows. Overall, the review assesses the huge potential of metabolomics 
for application in the process of drug/bioactive discovery from plants.  
The degeneration of neurons in specific brain regions is one of the main causes of 
chronic neurodegenerative diseases (NDs) and the formation of aggregates of 
misfolded proteins has been considered a hallmark underlying the pathophysiology of 
these diseases. Kostelidou et al. discussed the available microbial (bacteria and yeast) 
genetic screens and selection systems targeting NDs-associated protein misfolding, 
which facilitate the identification of cellular factors and disease processes as well as the 
discovery of synthetic and natural compounds with protective activities.  
As the simplest eukaryotic organism yeast shares fundamental biological processes 
with mammalian cells, including some processes associated with human diseases. This 
feature allows the use of Saccharomyces cerevisiae as test-tubes to decipher the 
molecular mechanisms underlying disease pathology as well as to accelerate the 
discover of protective molecules. In addition, mammalian cell models have been widely 
used in polyphenol research to identify/validate polyphenol bioactivity for chronic 
diseases. Rosado-Ramos et al. reviewed the use of eukaryotic cell models of NDs and 
their contribution for the identification of novel bioactivities as well as the benefits and 
limitations of their use as tools in the search for bioactive polyphenols.  
The use of the nematode Caenorhabditis elegans has been largely explored in aging 
research and, more recently, to investigate the multi-faceted properties of polyphenols 
as protective candidates for aging-related conditions. In this issue, Papaevgeniou & 
Chondrogianni compiled the studies addressing the anti-aging and neuroprotective 
potential of polyphenols using C. elegans as multicellular model organism.  
Epidemiological evidence suggests that polyphenol-rich diets lower the risk of certain 
cancers whereas epidemiological, in vitro, in vivo and clinical studies point to the fact 
that natural polyphenols can be potentially used for the prevention and treatment of 
cancer. Momtazi et al. reviewed the effects of curcumin on nasopharyngeal cancer, a 
rare type of head and neck cancer that is mainly treated by radiotherapy. Curcumin is a 
well-established polyphenol with chemosensitizing, chemotherapic and 
radiosensitizing effects and its chemopreventive potential has been studied in a variety 
of cancers. The authors highlight recent studies showing that curcumin has therapeutic 
and radio-sensitizing effects on nasopharyngeal cancer cells as well their mechanism of 
action. Overall, the potential of using curcumin as co-adjuvant of chemotherapy 
without secondary systemic toxic effects in humans is discussed. Besides cancer, the 
therapeutic benefits of curcumin have also been described for inflammatory processes, 
immunological disorders, diabetes, and oxidative stress. The molecule has a unique 
molecular structure that easily interacts with biomolecules like protein and enzymes, 
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thereby impacting their function/activity. Hatamipour et al. discussed the underlying 
mechanisms responsible for those chemical interactions of curcumin. 
The cardiovascular system is another field where the protective activity of polyphenols 
is well documented, particularly for atherosclerosis, hypertension, myocardial 
infarction, anthracyclin-induced cardiomyopathy, angiogenesis and heart failure. 
Santos et al. reviewed the knowledge of the main pharmacological effects and 
mechanisms of cardioprotection mediated by polyphenols in the heart and vessels 
obtained, from in vitro, animal and human studies. 
Hydroxytyrosol, and its derivatives from virgin olive oil, are important phytochemicals 
with proved activity for lifestyle-associated pathologies such as cancer, cardiovascular 
and neurodegenerative diseases, as indicated by epidemiological evidences. Hazas et 
al. reviewed its natural occurrence, metabolic fate and bioavailability as well its health 
beneficial effects together with newest perspectives on the mechanisms of action 
based on in vitro and animal studies. The authors concluded that hydroxytyrosol, and its 
derivatives, could have potential clinical use in cardiovascular diseases. However, more 
epidemiological data is needed to evaluate their preventive effects for NDs and cancer.  
Diabetes is a chronic metabolic disorder associated with several comorbidities, 
including diabetic retinopathy (DR), and increased oxidative stress in the retina seems 
to trigger the damage of both neuronal and vascular cells. Ola et al. reviewed the 
evidence pointing out the potential metabolic sources and pathways related to the 
increase of oxidative stress in DR and the role of dietary flavonoids, particularly 
flavonones, flavanols, flavonols, isoflavones, flavones and anthocyanins, in the 
modulation of redox homeostasis in diabetic retina.  
Given the myriad of bioactivities described for polyphenols, these molecules have 
emerged as lead compounds for the design and synthesis of improved molecules with 
therapeutic application for several diseases. Almeida et al. described how organic 
synthesis has been essential for the development of these new analogues, providing a 
wide range of structural modifications for structure-activity relationship studies and 
improving/modulating the biological activity of promising compounds. 
The studies reviewed in this issue unequivocally show the potential of polyphenols to 
modify pathological processes associated with chronic diseases and the efforts of 
organic chemistry to develop novel molecules with improved activity. Nonetheless, the 
majority of these compounds are still obtained from plant material by means of costly 
and inefficient extraction procedures. Dudnik et al. reviewed the use of metabolic 
engineering and microbial cell factories (Escherichia coli, S. cerevisiae, Corynebacterium 
glutamicum and Lactococcus lactis) as emerging alternatives allowing efficient and 
sustainable production of protective polyphenols.  
Overall, eleven outstanding international experts were invited to contribute to this 
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thematic issue and to share their opinions, with perspectives of polyphenol reseach for 
the advance in therapy for chronic diseases. We hope the multidisciplinary topics 
discussed with the theme issue will promote further discussion among 
pharmaceutical/nutraceutical industry and researchers. 
 
 
 
